VRDN Latest Press Releases

-- November 9, 2026 --

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing Business Wire 7:01 AM

-- November 6, 2026 --

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026 Business Wire 4:01 PM

-- November 4, 2026 --

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress Business Wire 7:01 AM

-- October 20, 2026 --

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 Business Wire 4:00 PM

-- August 6, 2026 --

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results Business Wire 7:01 AM

-- June 29, 2026 --

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones Globe Newswire 9:50 AM

-- June 26, 2026 --

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease Business Wire 6:00 PM

Market Data Delayed 15 Minutes